Bioplus Life Sciences is an integrated cGMP biopharmaceutical CRDMO driven by a strong culture of research, innovation, and scientific excellence.
We partner with global pharmaceutical and biotech companies to deliver end-to-end development and manufacturing solutions from preclinical and formulation development to pilot scale-up and full-scale commercial production.
UK MHRA, EU GMP, TGA, Health Canada
Intermediates, APIs & Finished Dosage Forms
Tablets & Capsules per year
International presence & reach
From early-stage development to full-scale commercial manufacturing, our integrated capabilities cover every step of the pharmaceutical value chain.
High-quality chemical intermediates for pharmaceutical synthesis, leveraging our integrated fermentation and chemical manufacturing capabilities with rigorous quality control.
Integrated platform for APIs through precision fermentation, metabolic engineering, and synthetic chemistry - from early-stage research to commercial production at scale.
Oral solid dosage forms, liquids, semi-solids, and novel drug delivery systems developed using a Quality by Design (QbD) approach for global regulated markets, supported by end-to-end capabilities from formulation development through scale-up and commercial manufacturing.
A seamless, fully integrated development and manufacturing journey guided by scientific rigor and regulatory expertise.
Preclinical API development, metabolic engineering, and synthetic biology platforms.
QbD-driven formulation design covering oral solids, liquids, semi-solids and NDDS.
Seamless technology transfer from pilot scale to commercial production.
Regulatory submissions, market authorization, and global product commercialization.
A broad spectrum of pharmaceutical capabilities, all under one integrated roof - from molecule discovery to commercial launch.
End-to-end QbD-driven formulation development, technology transfer, scale-up, and commercial manufacturing from our MHRA-approved facility.
Precision fermentation using E. coli, Pichia, yeasts, and fungi. 50 KL installed capacity with 100 KL expansion underway.
Multi-step synthesis across ~75 KL reactor capacity — alkylation, acylation, bromination, chiral, and heterocyclic chemistry.
Enzymatic biocatalysis, solvent reduction strategies, and waste minimisation aligned with ICH Q3 guidelines.
Amino acids, biopolymers, fatty acid derivatives, and chiral intermediates from fermentation-derived and synthetic routes.
Modified-release pellets, multi-layer tablets, gastro-resistant, and targeted drug delivery platforms.
eCTD dossier preparation, regulatory filing, and product registration for UK, EU, AU, NZ, and emerging markets.
Three strategically located facilities across Bangalore and Hosur, designed to meet the world's most stringent regulatory standards.
State-of-the-art Oral Solid Dosage facility
Integrated API development & fermentation campus
100 KL Hosur expansion + new OSD facilities planned
Our certifications enable market entry across regulated markets globally.
Medicines & Healthcare products Regulatory Agency
Since 2023
Danish Medicines Agency
Since 2006
Canadian Health Authority
Since 2011
Therapeutic Goods Administration
Since 2010
Registered humanitarian supplier
Since 2019
Sustainability & Corporate Governance
Since 2023
US Customs Trade Partnership
Since 2023
Supplier Security Compliance Initiative
Since 2024
Halal Certification
Since 2007
Testing & Calibration Laboratories
Since 2023
